Curaleaf Holdings (CURLF) Receivables (2019 - 2025)
Curaleaf Holdings (CURLF) posted quarterly Receivables of $81.4 million for Q4 2025, up 18.44% year-on-year from $68.8 million in Q4 2024, and up 18.44% on a QoQ basis from $68.8 million in Q4 2024.
Curaleaf Holdings (CURLF) Receivables (2019 - 2025) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Receivables for 7 consecutive years, with $81.4 million the latest figure, recorded in Q4 2025.
- Quarterly Receivables rose 18.44% year-over-year to $81.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $81.4 million (up 18.44% YoY) and the FY2025 annual result came in at $81.4 million, up 15.03% from the prior year.
- Receivables advanced to $81.4 million in Q4 2025 per CURLF's latest filing, from $68.8 million in the prior quarter.
- Over the last five years, Receivables for CURLF reached as high as $66.8 billion in Q1 2022 and fell as low as -$4000.0 in Q1 2021.
- A 5-year average of $5.2 billion and a median of $56.8 million in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables surged 1670225100.0% — and 2023, when it slumped 37.92%.
- Year by year, Receivables stood at $2.4 million in 2021, then surged by 1961.76% to $50.0 million in 2022, then rose by 24.81% to $62.4 million in 2023, then rose by 10.22% to $68.8 million in 2024, then climbed by 18.44% to $81.4 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $81.4 million, $68.8 million, and $62.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 81.43 Mn |
| Dec 31, 2024 | 68.75 Mn |
| Dec 31, 2023 | 62.38 Mn |
| Sep 30, 2023 | 38.06 Mn |
| Jun 30, 2023 | 46.67 Mn |
| Dec 31, 2022 | 49.98 Mn |
| Sep 30, 2022 | 61.31 Mn |
| Jun 30, 2022 | 64.65 Mn |
| Mar 31, 2022 | 66.81 Bn |
| Dec 31, 2021 | 2.42 Mn |
| Sep 30, 2021 | 56.76 Mn |
| Jun 30, 2021 | 49.67 Mn |
| Mar 31, 2021 | -4,000.00 |
| Dec 31, 2020 | 15,000.00 |
| Sep 30, 2020 | -14.10 Mn |
| Mar 31, 2020 | -14.60 Mn |
| Dec 31, 2019 | -35.44 Mn |
| Sep 30, 2019 | -24.00 Mn |